title: Profiles of resting potentials across the stria vascularis in kanamycin-deafened guinea pigs.
abstract: The resting potentials of the marginal cells in the stria vascularis of the guinea pig were determined from changes in the combined electrode-tissue resistance of the electrode. The resistance of the electrode was 45.5 +/- 16.0 M omega (n = 20) before penetration of the stria vascularis and 46.7 +/- 17.3 M omega (n = 20) after penetration. The resistance drops across the luminal membrane of the marginal cells were 46.0 +/- 22.6 M omega (n = 12) in kanamycin-deafened guinea pigs and 54.5 +/- 33.1 M omega (n = 9) in normal guinea pigs. The endocochlear potential (EP) and resting potentials in the marginal cells were 90.1 +/- 6.0 mV (n = 14) and 70.4 +/- 11.3 mV (n = 14) in kanamycin-deafened guinea pigs and 84.8 + 5.1 mV (n = 29) and 74.7 +/- 11.7 mV (n = 29) in normal guinea pigs. The resting potentials in the marginal cells decreased gradually and were approximately 0 mV around 20 min after anoxia in both kanamycin-deafened and normal guinea pigs. These changes were comparable to those of EP in kanamycin-deafened guinea pigs during anoxia. The mechanism of the EP in kanamycin-deafened guinea pigs is discussed.
authors.affiliation: Department of Otorhinolaryngology, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Komune
authors.forename: H
authors.initials: H
authors.lastname: Inoue
authors.forename: S
authors.initials: S
authors.lastname: Wakizono
authors.forename: T
authors.initials: T
authors.lastname: Nakagawa
authors.forename: T
authors.initials: T
authors.lastname: Kimitsuki
authors.forename: T
authors.initials: T
authors.lastname: Uemura
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D003638:Deafness / Q000209:etiology; D005071:Evoked Potentials / Q000502:physiology*; D006168:Guinea Pigs; D000860:Hypoxia / Q000139:chemically induced / Q000150:complications; D007612:Kanamycin / Q000009:adverse effects* / Q000493:pharmacokinetics; D013316:Stria Vascularis / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D007612:Kanamycin